---
document_datetime: 2023-09-21 20:45:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/sugammadex-mylan-epar-all-authorised-presentations_en.pdf
document_name: sugammadex-mylan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8908194
conversion_datetime: 2025-12-28 02:08:36.326263
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/21/1583/001 | Sugammadex Mylan  | 100 mg/ml  | Solution for injection | Intravenous use           | vial (glass)          | 2 ml                      | 1 vial      |
| EU/1/21/1583/002 | Sugammadex Mylan  | 100 mg/ml  | Solution for injection | Intravenous use           | vial (glass)          | 2 ml                      | 10 vials    |
| EU/1/21/1583/003 | Sugammadex Mylan  | 100 mg/ml  | Solution for injection | Intravenous use           | vial (glass)          | 5 ml                      | 1 vial      |
| EU/1/21/1583/004 | Sugammadex Mylan  | 100 mg/ml  | Solution for injection | Intravenous use           | vial (glass)          | 5 ml                      | 10 vials    |